Further Validation of the Peripheral Artery Questionnaire: Results from a Peripheral Vascular Surgery Survey in the Netherlands  by Smolderen, K.G. et al.
Eur J Vasc Endovasc Surg (2008) 36, 582e591Further Validation of the Peripheral Artery
Questionnaire: Results from a Peripheral Vascular
Surgery Survey in the NetherlandsK.G. Smolderen a, S.E. Hoeks b, A.E. Aquarius a, W.J. Scholte op Reimer c,
J.A. Spertus d, H. van Urk e, J. Denollet a, D. Poldermans b,*a CoRPS e Center of Research on Psychology in Somatic Diseases, Department of Medical Psychology, Tilburg University,
Tilburg, The Netherlands
b Department of Anaesthesiology, Erasmus Medical Center, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
c Amsterdam University of Applied Sciences, School of Nursing, Amsterdam, The Netherlands
d Mid America Heart Institute of Saint Luke’s Hospital, Kansas City, Mo, United States
e Department of Vascular Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
Submitted 9 May 2008; accepted 24 July 2008
Available online 18 September 2008KEYWORDS
Peripheral arterial
disease;
Health status;
Quality of life;
Outcomes* Corresponding author. Dr. Don Po
Rotterdam, Netherlands. Tel.: þ31 10
E-mail address: d.poldermans@era
1078-5884/$34 ª 2008 European Socie
doi:10.1016/j.ejvs.2008.07.015Abstract Objectives: Peripheral arterial disease (PAD) is associated with adverse cardiovas-
cular events and can significantly impair patients’ health status. Recently, marked methodo-
logical improvements in the measurement of PAD patients’ health status have been made.
The Peripheral Artery Questionnaire (PAQ) was specifically developed for this purpose. We vali-
dated a Dutch version of the PAQ in a large sample of PAD patients.
Design: Cross-sectional study.
Methods: The Dutch PAQ was completed by 465 PAD patients (70% men, mean age 65 10 years)
participating in theEuroHeartSurveyProgramme.Principal componentsanalysis andreliabilityanal-
yseswereperformed.Convergent validitywasdocumentedbycomparing thePAQwithEQ-5D scales.
Results: Three factorswere discerned; Physical Function, PerceivedDisability, and Treatment Satis-
faction (factor loadings between 0.50 and 0.90). Cronbach’s a values were excellent (mean
aZ 0.94). Shared variance of the PAQ domains with EQ-5D scales ranged from 3 to 50%.
Conclusions: The Dutch PAQ proved to have good measurement qualities; assessment of Physical
Function, Perceived Disability, and Treatment Satisfaction facilitates the monitoring of patients’
perceived health in clinical research and practice. Measuring disease-specific health status in a reli-
able way becomes essential in times were a wide array of treatment options are available for PAD
patients.
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Validation of Dutch Peripheral Artery Questionnaire 583Introduction ethics committees of the participating centers and allPatients with peripheral arterial disease (PAD) constitute
a high-risk group that needs stringent risk management and
monitoring. Atherosclerotic processes underlying the
disease affect different vascular beds simultaneously and
predispose PAD patients to a variety of cardiovascular
conditions such as claudication, myocardial infarction, and
stroke.1 Increasing awareness of PAD and its consequences
is especially needed in lower-extremity PAD.2,3 Apart from
the disease burden itself,4 patients are confronted with
multiple challenges due to the chronic nature of their
disease and the multifaceted risk management and treat-
ment options that are available to them. PAD patients
should be routinely offered stringent risk management
treating associated conditions such as hypertension and
hyperlipidemia and, where indicated, endovascular proce-
dures and surgery may bring relief.1 When it comes to the
evaluation of medical therapy and existing revasculariza-
tion procedures, quantifying PAD patients’ health status
becomes an important issue.5 In fact, unlike the use of
percutaneous revascularization in the setting of an acute
myocardial infarction where treatment may improve
survival, the primary goal of revascularization procedures
in PAD is to improve patients’ symptoms, function and
quality of life. In order to monitor patients’ health status in
a reliable way, a sensitive disease-specific instrument is
needed.
Recently, marked methodological improvements in the
measurement of PAD patients’ health status (their symp-
toms, function and quality of life) have been made. The
psychometrically-sound Peripheral Artery Questionnaire
(PAQ), a disease-specific measure, was developed for this
purpose.6 This instrument already proved to be useful to
quantify improvement in health status after peripheral
endovascular revascularization.5 However, the PAQ is only
available in an English-language version, and the dimen-
sions it measures were created to represent a clinical
framework for quantifying patients’ health status and no
empiric data supporting a patient-centered framework of
the data has been performed. In order to make wider use of
the PAQ possible, and to facilitate comparisons of PAD care
and outcomes across different healthcare systems, we
translated and validated a Dutch version of the PAQ in
a large sample of Dutch PAD patients. More specifically, its
validity and reliability was examined; convergent validity
was tested against the EQ-5D, a standardized and widely
used health outcome instrument.7,8
Methods
Participants and design
This study was part of a survey of clinical practice that was
conducted between May and December 2004 in 11 hospitals
across the Netherlands. The study was performed within
the infrastructure of the Euro Heart Survey Programme,
a project that evaluates the implementation of guidelines
in daily clinical practice. Details of the participating
centers and information about data collection are
described elsewhere.9 The study was approved by the localpatients provided informed consent. All consecutive
patients included in this survey were seen at the partici-
pating vascular surgery departments and were undergoing
noncardiac elective vascular repair (endovascular or open
procedures). Endovascular procedures included aortic
endograft procedures and peripheral angioplasties with and
without stenting. Open procedures included: elective
abdominal aortic surgery, carotid endarterectomy, or
infrainguinal arterial reconstruction. Patients below the
age of 18 years and patients undergoing thoracic or brain
surgery were excluded. The study was approved by the
local ethics committees of the participating centers and all
patients provided informed consent. After three years,
information on vital status was obtained from the Civil
Registries. All survivors were contacted to complete health
status questionnaires.
Translation of the instrument
Forward and backward translation according to the World
Health Organization translation method was applied.10
Forward translations were made by two different trans-
lators whose native language was Dutch. These translations
were combined for making a first agreed-upon forward
translation. Two other members of the bilingual group then
evaluated the quality of this first version regarding clarity
and readability, and checked for further inconsistencies in
the translation. Adaptations upon this evaluation were
amended where appropriate. Next, monolingual individuals
were asked to read the first forward translation version
through and check for comprehensibility. These individuals
were PAD patients recruited at the vascular outpatient
clinic of a teaching hospital at the St.-Elisabeth Hospital,
the Netherlands. Comments of the monolingual group that
were compatible with the meaning of the original docu-
ment were inserted in the first forward translation version.
Subsequently, a back-translated version was obtained from
a professional translator. Finally, the original and back-
translated documents were set side-by-side by the bilingual
expert group and were reviewed for accuracy and equiva-
lence of the translation. The final version of the Dutch
translation is presented in appendix A and information
about the interpretation of scores is added in appendix B.
Measures
Demographic and clinical variables
Demographic variables included age and sex. Patients’
medical history was documented by their hospital charts at
the time of inclusion and included previous cardiovascular
history (angina pectoris, myocardial infarction, heart
failure, stroke/transient ischemic attack, arrhythmia,
valvular disease, and previous revascularization), clinical
risk factors (obesity, current smoking, hypertension, dia-
betes mellitus, renal insufficiency, and chronic obstructive
pulmonary disease), and type of surgery (endovascular,
open). Obesity was defined as having a Body Mass Index
30. Hypertension was recorded in patients presenting
with a blood pressure of 140/90 mm Hg or who were
treated for hypertension. Diabetes mellitus was recorded if
patients had a fasting glucose level of 7.0 mmol/l, or if
584 K.G. Smolderen et al.they received treatment for diabetes. Renal insufficiency
was recorded in patients with a serum creatinine level
2.0 mg/dl or in those who required dialysis.
Health status
Disease-specific health status was measured by the trans-
lated Dutch version of the PAQ; the instrument consists of
20 items with one item identifying the most symptomatic
leg and the other items being answered along variable
Likert response scales with equidistant gradations of
response. Six domains were initially discerned in the PAQ:
Physical Function, Symptoms, Symptom Stability, Social
Limitation, Treatment Satisfaction, and Quality of Life.6
Given that the response categories are different across
items, standardized scoring algorithms are applied to
obtain scale scores ranging from 0 to 100, with high scores
indicating good health status.6 Previously, the instrument
proved to be internally reliable (Cronbach’s a ranging from
0.80 to 0.94) and sensitive to clinical improvement in
a study with patients undergoing elective percutaneous
peripheral revascularization.6 The convergent validity of
the PAQ was established against existing health status
questionnaires, including the Walking Impairment Ques-
tionnaire, the 36-item Short-Form Health Survey (SF-36),
and an exercise treadmill test.6
To assess the convergent validity of the Dutch PAQ, the
Dutch version of the EQ-5D was used, a standardized,
generic instrument for describing and valuing health that
was designed by the EuroQol Group (an international
research network established in 1987).11,12 The EQ-5D
consists of a descriptive system that defines health along
five dimensions and a visual analogue scale (EQ VAS). The
five dimensions include: mobility, self care, usual activities,
pain or discomfort, and anxiety or depression. Each
dimension can be rated on three levels, ranging from no
problems to extreme problems and this score can be
dichotomized. The EQ VAS asks respondents to rate their
perception of their overall health on a vertical visual
analogue scale with the endpoints ranging from 0 to 100
(0Z ‘worst imaginable health state’ and 100Z ‘best
imaginable health state’). In this study, the EQ VAS, the EQ-
5D index, and the dichotomous dimension scores (1Z no
problems, 0Z some or extreme problems) were used in the
analyses.13 The EQ-5D index, a single summary index,
calculated in this study was based on value sets derived
from the Dutch population.14,15
Statistical analysis
Baseline characteristics were described for the total
sample and differences between responders and non-
responders regarding these variables were examined using
Student’s t-tests for continuous variables and chi-square
tests for dichotomous variables to assess for potential
selection biases among those who participated in the
current study. Missing values were also checked on item-
level for the PAQ. To assess the suitability of the data for
factor analysis, Bartlett’s test of sphericity and the Kaisere
MeyereOlkin measure of sampling adequacy were checked.
Principal components analysis (PCA) was applied to deter-
mine the number of factors present in the PAQ. Factors
with an eigenvalue of 1.0 or more were retained for furtherinvestigation. Varimax rotation was used to interpret the
pattern of loadings on the identified factors. Internal
consistency of the factors was examined by performing
reliability analyses. Cronbach’s alpha coefficients were
used as indicators of internal consistency. Convergent val-
idity of the PAQ was evaluated by correlating the extracted
PAQ subscales and Summary score with the dichotomized
subscales of the EQ-5D (point-biserial correlations), the EQ
VAS, and the EQ-5D index and by calculating the shared
variance (r2 in %) between the PAQ and the EQ domains. In
addition, PAQ summary and domain scores were stratified
by dichotomized EQ-5D subscales (Student’s t-tests). All
analyses were performed using SPSS for Windows, version
14.0.1 (SPSS Inc., Chicago, Illinois).
Results
The total study population consisted of 711 patients.
Patient status could be determined in 701 (99%) of the
original 711 respondents revealing that 149 (21%) of
patients had died in the three year period since the original
survey. All 552 survivors were contacted to complete health
status questionnaires (EQ-5D and PAQ), 465 (84%) of whom
responded and comprised the final study group. The current
sample (nZ 465) included 70% (nZ 323) male patients and
the mean age was 65 years (SDZ 10 years). There were 245
(52.7%) of patients who underwent an endovascular
procedure; 27 patients underwent an aortic endograft
procedure, 216 peripheral angioplasties with or without
stenting, and 2 others. A total of 220 (47.3%) patients
underwent an open procedure; 22 patients underwent
carotid endarterectomy, infrainguinal arterial reconstruc-
tion nZ 101, abdominal aortic surgery nZ 88 and 9 other
open procedures. Information about associated risk factors
and procedure information is presented in Table 1.
Responders did not differ from non-responders, except
for current smoking (52.9% in non-responders vs. 35.5% in
responders, pZ 0.002) and the presence of arrhythmia
(16.1% in non-responders vs. 6.5% in responders,
pZ 0.002). The total of missings on the PAQ items ranged
from 2.8 to 14.2% (meanZ 5.5%), with the questions con-
cerning treatment satisfaction yielding the largest amount
of missings.
Measurement qualities of the PAQ
Factor analyses were performed on all PAQ items (except
for the first item that indicates the most symptomatic leg)
for the total sample (nZ 465). Three factors explained the
most of the variance in the observed data (using the
criterion of eigenvalues above 1.0) and therefore three
factors were retained in the final model (Table 2). The first
factor explained 58%, the second 10%, and the third 5%. A
more than three factor solution did not significantly add to
the interpretability of the data (explaining only residual
variance between 4 and 0.4%). Items are presented and
numbered according to the order of the original instru-
ment. All PAQ items had factor loadings ranging from 0.50
to 0.90. Two out of three factors corresponded almost
exactly with the original Physical Function domain (items
2aef) and exactly with the Treatment Satisfaction scale
(items 7e9). The new factor was a combination of the
Table 1 Characteristics of the total sample (nZ 465)
Demographics
Mean age SD, year 65 10
Male sex, n (%) 323 (70)
Cardiovascular history, n (%)
Angina pectoris 73 (16)
Myocardial infarction 67 (14)
Heart failure 18 (4)
Stroke or TIA 69 (15)
Arrhythmia 30 (7)
Valvular disease 23 (5)
Previous revacularization 77 (17)
Clinical risk factors, n (%)
Obesity 57 (12)
Current smoker 165 (36)
Hypertension 177 (38)
Diabetes mellitus 96 (21)
Renal insufficiency 24 (5)
COPD 49 (11)
Surgical procedure, n (%)
Endovascular 245 (53)
Open 220 (47)
TIAZ transient ischemic attack; and COPDZ chronic obstruc-
tive pulmonary disease.
Validation of Dutch Peripheral Artery Questionnaire 585original Symptom, Symptom Stability, Social Limitation,
and Quality of Life domains (items 3-13c). This new domain
was called ‘Perceived Disability’ because these items
require patients to evaluate their disabilities. Items with
double loadings (4, 11, 13aec) were allocated according to
their original domain in order to preserve the ‘clinical’
framework of the original instrument6 (Table 2). The
Summary score was computed by averaging the Physical
Function and Perceived Disability scores.
Reliability was documented using Cronbach’s a; Cron-
bach’s a for the Physical Function domain was 0.95, for the
Perceived Disability domain 0.93, and for the Treatment
Satisfaction domain 0.91. The Cronbach’s a for the
Summary scale was 0.96. Mean inter-item correlation for
the Physical Function domain was 0.76, for the Perceived
Disability 0.58, for Treatment Satisfaction 0.78, and for the
Summary score 0.71.
Convergent validity of the PAQ
Correlations between the PAQ subscales, PAQ Summary
score, and the dichotomized subscales of the EQ-5D, the EQ
VAS, and the EQ-5D index are presented in Table 3. Shared
variance between the PAQ Physical Function domain and the
EQ-5D scales ranged from 10 to 49%. The shared variance
of the Perceived Disability domain scores of the PAQ and the
EQ-5D scores ranged from 14 to 50%. The Treatment Satis-
faction domain and the EQ-5D domains only shared 3e22%
of variance. The shared variance between the Summary PAQ
score and the EQ-5D scores ranged from 12 to 50%.
The intercorrelations of the PAQ are also presented in
Table 3 (shared variance between 18 and 92%). The inter-
correlations with the Treatment Satisfaction scale, were
relatively smaller (0.43e0.60) as compared with theintercorrelations of the other domains and the Summary
score (0.78e0.96).
Mean PAQ Summary scores and PAQ domain scores were
significantly different (p< 0.0001) for high vs. low health
status patients groups that were created by stratifying the
total sample according to the five dichotomized subscales
of the EQ-5D (Figure 1).
Discussion
In order to make wider use of the PAQ possible, the ques-
tionnaire was translated into Dutch and validated in a study
of Dutch PAD patients that was performed within the
infrastructure of the Euro Heart Survey Programme. It is the
first translated version of the PAQ that was developed and
the first study that evaluated its factorial structure within
a relatively large study sample. A high response rate and
the missing analysis on item-level showed that the PAQ was
well accepted in the current sample of PAD patients. Unlike
in the original instrument, three factors were discerned in
the Dutch version of the PAQ, explaining most of the vari-
ance in the observed data. Two factors overlapped
completely with the previously proposed Physical Function
and Treatment Satisfaction scales of the original instru-
ment. The other original domains (Symptom, Symptom
Stability, Social Limitation, and Quality of Life) were
combined in a new domain, which we labeled the Perceived
Disability domain in our study. As we chose to stay close to
the clinically interpretable domains that were defined in
the original instrument, we accordingly allocated double-
loaded items. Future studies therefore need to replicate
our work in both American and European samples to get an
internationally agreed-upon factor structure. The three
domains identified in this study were internally reliable.
The convergent validity was established using a well stan-
dardized generic health status questionnaire, the EQ-5D.7
Convergent validity of the PAQ domains was documented by
medium to large correlations with the EQ-5D and by
comparisons of the mean scores of the PAQ scales with the
stratified EQ-5D domains. Both the intercorrelations of the
PAQ domains and the correlations of the Treatment Satis-
faction domain with the EQ-5D scales pointed to the
uniqueness of the Treatment Satisfaction domain. Inter-
correlations of the PAQ domains Perceived Disability and
Physical Function were all high, indicating that the domains
were strongly related to the construct that the question-
naire purported to measure, namely disease-specific health
status.
Measuring disease-specific health status in a reliable way
becomes essential in times were a wide array of treatment
options are available for PAD patients. Recent technological
advances have also resulted in a shift from open surgical
procedures toward lower-morbidity catheter-based inter-
ventional therapies.16,17 Although the use of these cath-
eter-based interventions has increased significantly, the
results regarding long-term patency rates of these inter-
ventions are mixed.18 Due to the variety in treatment
options and their variable success rates, PAD management
has become a complex and challenging task. Treatment
should therefore be tailored to the individual patient and
should take into account the patients’ perspective. To
facilitate such discussions with patients, patient-based
Table 2 Sample pattern matrices of PAQ scale items as indicated by principal component analysesa
Total (nZ 465)
Factor I physical
function
Factor II perceived
disability
Factor III treatment
satisfaction
Physical function
2a-Walking around your home 0.70 0.34 0.19
2b-Walking 1e2 blocks on level ground 0.85 0.30 0.16
2c-Walking 1e2 blocks up a hill 0.88 0.22 0.19
2d-Walking 3e4 blocks on level ground 0.88 0.24 0.15
2e-Hurrying or jogging 0.87 0.15 0.20
2f-Vigorous work or exercise 0.87 0.19 0.19
Perceived disability
3-Symptoms of PAD have changed 0.29 0.66 0.01
4-How often PAD symptoms 0.54 0.54 0.31
5-How much has PAD bothered you 0.55 0.63 0.31
6-Awakened with PAD symptoms 0.26 0.56 0.28
10-Limited enjoyment of life 0.42 0.63 0.42
11-Spend rest of life with PAD like it is now 0.41 0.50 0.50
12-Felt discouraged or down in the dumps 0.38 0.62 0.40
13a-Limited participation in hobbies, recreation 0.59 0.57 0.32
13b-Limited participation in visiting family, friends 0.56 0.59 0.18
13c-Limited participation in working or doing household chores 0.62 0.56 0.23
Treatment satisfaction
7-Satisfied that everything possible is being done 0.19 0.21 0.85
8-Satisfied with explanations 0.14 0.10 0.90
9-Satisfied with current treatment 0.19 0.21 0.85
a Varimax rotation; loadings of items assigned to a factor are presented in bold face.
586 K.G. Smolderen et al.outcomes also need to be included in randomized trials
evaluating revascularization procedures and medication
use in PAD patients. Generic health status instruments are
not sensitive enough to provide clinicians and researchers
with useful information that makes adequate evaluation of
PAD treatments possible.6,19,20 Several disease-specific
health status measures are developed for this purpose, with
the PAQ being an excellent example of a valid and sensitiveTable 3 Correlation matrix of the PAQ scales and EQ-5D scales
Correlation matrixa
PAQ physical function PAQ perceived
PAQ
Physical function e
Perceived disability 0.78 e
Treatment satisfaction 0.43 0.60
Summary score 0.96 0.93
EQ-5D
Mobility 0.66 0.59
Daily activities 0.67 0.65
Self care 0.40 0.38
Pain 0.61 0.61
Anxiety/depression 0.32 0.38
EQ-5D Index 0.65 0.67
EQ-VAS 0.70 0.71
PAQZ peripheral artery questionnaire; EQ-5DZ EuroQol, and VASZ
a All correlations were significant at the 0.01 level.instrument that could be used both in clinical practice and
as a treatment outcome in clinical PAD trials.5,6
The term ‘health status’ was chosen to refer to the
construct that the PAQ intends to measure. However, the
items that are contained in the PAQ do not all fully corre-
spond with the definition of health status: ‘‘physical,
mental, and social functioning assessment, but without the
subjective evaluation of the patient’’.21 The questionnaire(nZ 465)
disability PAQ treatment satisfaction PAQ summary score
e
0.54 e
0.36 0.64
0.35 0.66
0.18 0.38
0.42 0.62
0.17 0.35
0.38 0.66
0.47 0.71
visual analogue scale.
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Figure 1 Mean PAQ domain and Summary scores and standard deviations stratified by dichotomized EQ-5D subscales (nZ 465).
All differences were significant at the p< 0.0001 level. (1) Mobility, (2) Daily Activities, (3) Self Care, (4) Pain, (5) Anxiety/
Depression.
Validation of Dutch Peripheral Artery Questionnaire 587is actually a mixture of items that deal with patients’
health status and items that assess quality of life, with
quality of life referring to patients’ personal evaluation of
their functioning, disease, and treatment.22,23
The Physical Function domain of the PAQ is an example
of a scale measuring health status; it indicates whether PAD
caused limitations and classifies the levels of such limita-
tions.22 In the second domain, called Perceived Disability in
our study, a more subjective and evaluative character is
attributed to items 10e13c (e.g., If you had to spend the
rest of your life with your PAD the way it is right now, how
would you feel about this?). The third domain in our study
also refers to the personal evaluation of the treatment that
the patient received and is therefore more related to the
genuine quality of life concept.23 For clinical decision
making, both health status or the registration of limita-
tions, and quality of life, the extent to which these limi-
tations actually hamper the patient, need to be considered
and in this respect, the PAQ may offer insight in both. Other
disease-specific outcome measures that are available suffer
from predominantly focussing on the registration of limi-
tations and do not stress the subjective experience of the
disease and its limitations. The Walking Impairment Ques-
tionnaire, for example, only assesses the degree of physical
limitation that the PAD patient experiences24 and although
the developers of the Intermittent Claudication Question-
naire claim to measure quality of life, thirteen out of
sixteen items only register limitations with physical, mental
and social functioning and do not evaluate the degree of
dissatisfaction with these limitations.25 The VascularQuality of Life Questionnaire, on the other hand, contains
items that tap both the patients’ health status and quality
of life, but the instrument contains both questions for PAD
patients with intermittent claudication and critical leg
ischemia, making this instrument more generic.26
This study has some limitations that should be consid-
ered when interpreting our results. The most important
limitation is the cross-sectional nature of this study. We
only assessed patients’ health status with the PAQ on
a single point of time and issues regarding reproducibility
and sensitivity to change were not examined. On the other
hand, previous studies with the PAQ convincingly showed
that the instrument had a good testeretest reliability and
that the instrument was sensitive to clinical improve-
ment.5,6 Another limitation is that our study population
only consisted of PAD patients that underwent vascular
surgery, which may limit the generalizability of scores to
PAD patients that received conservative treatment. In spite
of these limitations, potential strengths of our study were
the large sample size and the fact that our study population
consisted of patients of different hospitals across the
Netherlands. Furthermore, this study was the first to
extensively document on the factorial validity of the PAQ
and was able to reduce the number of factors from 6 to 3,
further facilitating its use in clinical practice.
In sum, the Dutch version of the PAQ was found to be
a reliable and valid instrument to assess the health status of
PAD patients. In contrast with the six domains of the original
instrument, a three factor solution was sufficient to explain
most of the variance in the health status scores of the present
588 K.G. Smolderen et al.study. The next step is to perform additional research to
establish the validity of the PAQwith relevant clinical indices,
such as walking performance and standardized disease-
specific risk classifications, and to monitor the performance
of the questionnaire in evaluating the benefit of PAD treat-
ments, as perceived by the individual patient. These efforts
should all contribute to the tailor-made management of PADpatients, in this era of multifaceted risk management and
treatment options that are available to them.
Appendix A
The Dutch version of the Peripheral Artery
Questionnaire
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Interpretation of raw scores e patients undergoing
vascular surgery in the Netherlands (nZ 465)
The following table can be used for the interpretation of
raw scores on the PAQ scales.Mean (SD) 33 Percentile cut-off
scores to indicate poor
health status
Physical function 56.4 (33.5) 33
Perceived disability 67.2 (25.9) 57
Treatment satisfaction 77.4 (27.5) 75
Summary score 62.0 (28.2) 47References
1 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA,
Fowkes FG, et al. Inter-Society consensus for the management
of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg
2007;33(Suppl. 1):S1e75.
2 McDermott MM, Hahn EA, Greenland P, Cella D, Ockene JK,
Brogan D, et al. Atherosclerotic risk factor reduction inperipheral arterial disease: results of a national physician
survey. J Gen Intern Med 2002;17(12):895e904.
3 Al-Omran M, Lindsay TF, Major J, Jawas A, Leiter LA, Verma S.
Perceptions of Canadian vascular surgeons toward pharmaco-
logical risk reduction in patients with peripheral arterial
disease. Ann Vasc Surg 2006;20(5):555e63.
4 Aquarius AE, De Vries J, Henegouwen DP, Hamming JF. Clinical
indicators and psychosocial aspects in peripheral arterial
disease. Arch Surg 2006;141(2):161e6 [discussion 166].
5 Safley DM, House JA, Laster SB, Daniel WC, Spertus JA,
Marso SP. Quantifying improvement in symptoms, functioning,
and quality of life after peripheral endovascular revasculari-
zation. Circulation 2007;115(5):569e75.
6 Spertus J, Jones P, Poler S, Rocha-Singh K. The peripheral artery
questionnaire: a new disease-specific health status measure for
patients with peripheral arterial disease. Am Heart J 2004;
147(2):301e8.
7 Rabin R, de Charro F. EQ-5D: a measure of health status from
the EuroQol Group. Ann Med 2001;33(5):337e43.
8 Kind P. The EuroQol instrument: an index of health related
quality of life. In: Spilker B, editor. Quality of life and phar-
macoeconomics in clinical trials. 2nd ed. Philadelphia, PA:
Lippincott-Raven Publishers; 1996. p. 191e201.
9 Hoeks SE, Scholte op Reimer WJ, Lenzen MJ, van Urk H,
Jorning PJ, Boersma E, et al. Guidelines for cardiac manage-
ment in noncardiac surgery are poorly implemented in clinical
practice: results from a peripheral vascular survey in the
Netherlands. Anesthesiology 2007;107(4):537e44.
10 WHOQOLgroup. Development of the WHOQOL: rationale and
current status. Int J Ment Health 1994;23:24e56.
Validation of Dutch Peripheral Artery Questionnaire 59111 Brooks R. EuroQol: the current state of play. Health Policy 1996;
37(1):53e72.
12 EuroQolea new facility for the measurement of health-related
quality of life. The EuroQol Group. Health Policy 1990;16(3):
199e208.
13 EQ-5D value sets: Inventory, comparative review and user
guide. Eds. Szende A, Oppe M, Devlin N. EuroQoL Group
Monographs Volume 2. Springer, 2006.
14 Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF,
Busschbach JJ. The Dutch tariff: results and arguments for an
effective design for national EQ-5D valuation studies. Health
Econ 2006;15(10):1121e32.
15 Dolan P. Modelling valuations for health states: the effect of
duration. Health Policy 1996;38(3):189e203.
16 Anderson PL, Gelijns A, Moskowitz A, Arons R, Gupta L,
Weinberg A, et al. Understanding trends in inpatient surgical
volume: vascular interventions, 1980e2000. J Vasc Surg 2004;
39(6):1200e8.
17 White CJ, Gray WA. Endovascular therapies for peripheral
arterial disease: an evidence-based review. Circulation 2007;
116(19):2203e15.
18 Beckman JA. Peripheral endovascular revascularization: some
proof in the pudding? Circulation 2007;115(5):550e2.
19 de Vries M, Ouwendijk R, Kessels AG, de Haan MW, Flobbe K,
Hunink MG, et al. Comparison of generic and disease-specificquestionnaires for the assessment of quality of life in patients
with peripheral arterial disease. J Vasc Surg 2005;41(2):
261e8.
20 Mehta T, Venkata Subramaniam A, Chetter I, McCollum P.
Assessing the validity and responsiveness of disease-specific
quality of life instruments in intermittent claudication. Eur J
Vasc Endovasc Surg 2006;31(1):46e52.
21 De Vries J, Drent M. Quality of life and health status in inter-
stitial lung diseases. Curr Opin Pulm Med 2006;12(5):354e8.
22 Hamming JF, De Vries J. Measuring quality of life. Br J Surg
2007;94(8):923e4.
23 The World Health Organization Quality of Life assessment
(WHOQOL): development and general psychometric properties.
Soc Sci Med 1998;46(12):1569e85.
24 Regensteiner JG, Hiatt WR. Current medical therapies for
patients with peripheral arterial disease: a critical review. Am J
Med 2002;112(1):49e57.
25 Chong PF, Garratt AM, Golledge J, Greenhalgh RM, Davies AH.
The intermittent claudication questionnaire: a patient-assessed
condition-specific health outcome measure. J Vasc Surg 2002;
36(4):764e71 [discussion 863e864].
26 Morgan MB, Crayford T, Murrin B, Fraser SC. Developing the
vascular quality of life questionnaire: a new disease-specific
quality of life measure for use in lower limb ischemia. J Vasc
Surg 2001;33(4):679e87.
